Keywords
Eligibility Determination ×
Gastroenterology ×
Liver Cirrhosis ×
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

9 Search results.

Eligibility Liver Cirrhosis NCT02125071

- 6/30/20 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation; ODM derived from: https://clinicaltrials.gov/show/NCT02125071

Eligibility Liver Cirrhosis NCT01456286

- 6/30/20 - 1 form, 2 itemgroups, 15 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Randomized Controlled Trial to Assess the Effects of Sapropterin on Hepatic and Systemic Hemodynamics in Patients With Liver Cirrhosis and Portal Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT01456286

Eligibility Liver Cirrhosis NCT02508623

- 4/27/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices; ODM derived from: https://clinicaltrials.gov/show/NCT02508623

Haemodynamic effect of serelaxin in patients with cirrhosis and portal hypertension NCT01640964 - Eligibility Criteria

- 4/4/19 - 1 form, 6 itemgroups, 10 items, 1 language
Itemgroups: Eligibility inclusion criteria study part A, Eligibility inclusion criteria study part B, Eligibility inclusion criteria for study A and B, Eligibility exclusion criteria for study part A, Eligibility exclusion criteria for study part B, Eligibility exclusion criteria for study part A and B
The main purpose of this exploratory study was to investigate the effect of serelaxin (RLX030) infusion on the hepatic and renal circulation in patients with compensated cirrhosis and portal hypertension. Measurements were acquired non-invasively using magnetic resonance angiography (MRA) (study part A) and more directly via cannulation of the hepatic portal vein during a routine transjugular intrahepatic portosystemic shunt (TIPSS) check procedure (study part B), to determine the acute haemodynamic response to serelaxin (RLX030). ODM derived from: https://clinicaltrials.gov/show/NCT01640964

Eligibility Cirrhosis NCT02247414

- 3/1/19 - 1 form, 2 itemgroups, 16 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection; ODM derived from: https://clinicaltrials.gov/show/NCT02247414

Eligibility Cirrhosis With Hepatocellular Carcinoma NCT01798173

- 12/19/17 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01798173

Eligibility Liver Cirrhosis NCT00831337

- 8/4/17 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of Probiotics in the Treatment of Portal Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00831337

Eligibility Liver Cirrhosis DRKS00000811 NCT01361061 DRKS00000811 - Eligibility Liver Cirrhosis NCT01361061 DRKS00000811

- 6/30/17 - 1 form, 2 itemgroups, 5 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Responsible Party: Dominik Bettinger, investigator, University Hospital Freiburg ClinicalTrials.gov Identifier: NCT01361061 History of Changes Other Study ID Numbers: HCC3 DRKS00000811 ( Registry Identifier: German Clinical Trials Register ) Study First Received: May 16, 2011 Last Updated: December 14, 2011 AFP - L3% and DCP as Screening Marker for a Hepatocellular Carcinoma in Patients With Cirrhosis of the Liver ODM derived from: https://clinicaltrials.gov/ct2/show/NCT01361061

Eligibility Liver Cirrhosis NCT00304551

- 4/21/17 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC); ODM derived from: https://clinicaltrials.gov/show/NCT00304551